open access

Vol 86, No 1 (2018)
ORIGINAL PAPERS
Published online: 2018-02-28
Submitted: 2017-10-11
Accepted: 2017-12-11
Get Citation

Concentration of 8-isoprostanes in the exhaled breath condensate as a marker of oxidative stress in patients with type 1 diabetes

Anna Pękala-Wojciechowska, Michał Poznański, Kamil Szyszow, Adam Antczak
DOI: 10.5603/ARM.2018.0002
·
Pubmed: 29490415
·
Adv Respir Med 2018;86(1):3-6.

open access

Vol 86, No 1 (2018)
ORIGINAL PAPERS
Published online: 2018-02-28
Submitted: 2017-10-11
Accepted: 2017-12-11

Abstract

Introduction: Type 1 diabetes is an insulin deficiency-based chronic disease. It leads to the development of hyperglycaemia,
which plays a key role in the initiation and progression of tissue damage in patients with diabetes. This mostly results from
oxidative stress, whose increased severity is observed in this group of patients. Increased levels of 8-isoprostanes are seen in
many inflammatory diseases, including asthma, COPD and cystic fibrosis. These diseases demonstrated the usefulness of the
exhaled breath condensate (EBC) for extracting material for markers of oxidative stress, including 8-isoprostanes. The purpose
of this study was to assess the severity of oxidative stress measured with 8-isoprostane concentrations in the exhaled breath
condensate in healthy subjects and in patients with type 1 diabetes with and without vascular complications.

Material and methods: 33 patients assigned to the control group, type 1 diabetes without complications group and type 1 diabetes
group with advanced complications were included in the study. Retinopathy, nephropathy or neuropathy have been reported
as a criterion distinguishing between complicated and uncomplicated diabetes. EBC was obtained for each subject. 8-isoprostane
concentrations were determined in serum and EBC by ELISA.

Results and conclusions: Mean (± SD) blood levels of 8-isoprostane in patients with type 1 diabetes mellitus without complications
and those with type 1 diabetes with advanced complications were significantly higher compared to the control group
(178.17 [135.73] vs. 183.34 [200.41] vs. 47.13 [25.20] pg/ml; p < 0.05). The mean (± SD) concentration of 8-isoprostane in EBC
was lower in diabetic patients with type 1 diabetes with advanced complications than in patients with type 1 diabetes without
advanced complications and in the control group (8.32 [4.60] vs. 19.13 [22.35] vs. 28.17 [35.11] pg/ml; p < 0.05). Measurement
of 8-isoprostanes in the EBC in patients with type 1 diabetes does not appear to be a good diagnostic tool for monitoring the
activity of oxidative stress in these patients.

Abstract

Introduction: Type 1 diabetes is an insulin deficiency-based chronic disease. It leads to the development of hyperglycaemia,
which plays a key role in the initiation and progression of tissue damage in patients with diabetes. This mostly results from
oxidative stress, whose increased severity is observed in this group of patients. Increased levels of 8-isoprostanes are seen in
many inflammatory diseases, including asthma, COPD and cystic fibrosis. These diseases demonstrated the usefulness of the
exhaled breath condensate (EBC) for extracting material for markers of oxidative stress, including 8-isoprostanes. The purpose
of this study was to assess the severity of oxidative stress measured with 8-isoprostane concentrations in the exhaled breath
condensate in healthy subjects and in patients with type 1 diabetes with and without vascular complications.

Material and methods: 33 patients assigned to the control group, type 1 diabetes without complications group and type 1 diabetes
group with advanced complications were included in the study. Retinopathy, nephropathy or neuropathy have been reported
as a criterion distinguishing between complicated and uncomplicated diabetes. EBC was obtained for each subject. 8-isoprostane
concentrations were determined in serum and EBC by ELISA.

Results and conclusions: Mean (± SD) blood levels of 8-isoprostane in patients with type 1 diabetes mellitus without complications
and those with type 1 diabetes with advanced complications were significantly higher compared to the control group
(178.17 [135.73] vs. 183.34 [200.41] vs. 47.13 [25.20] pg/ml; p < 0.05). The mean (± SD) concentration of 8-isoprostane in EBC
was lower in diabetic patients with type 1 diabetes with advanced complications than in patients with type 1 diabetes without
advanced complications and in the control group (8.32 [4.60] vs. 19.13 [22.35] vs. 28.17 [35.11] pg/ml; p < 0.05). Measurement
of 8-isoprostanes in the EBC in patients with type 1 diabetes does not appear to be a good diagnostic tool for monitoring the
activity of oxidative stress in these patients.

Get Citation

Keywords

8-isoprostanes, exhaled breath condensate, oxidative stress, type 1 diabetes

About this article
Title

Concentration of 8-isoprostanes in the exhaled breath condensate as a marker of oxidative stress in patients with type 1 diabetes

Journal

Advances in Respiratory Medicine

Issue

Vol 86, No 1 (2018)

Pages

3-6

Published online

2018-02-28

DOI

10.5603/ARM.2018.0002

Pubmed

29490415

Bibliographic record

Adv Respir Med 2018;86(1):3-6.

Keywords

8-isoprostanes
exhaled breath condensate
oxidative stress
type 1 diabetes

Authors

Anna Pękala-Wojciechowska
Michał Poznański
Kamil Szyszow
Adam Antczak

References (18)
  1. Devries JH, Snoek FJ, Heine RJ. Persistent poor glycaemic control in adult Type 1 diabetes. A closer look at the problem. Diabet Med. 2004; 21(12): 1263–1268.
  2. Wentholt IME, Kulik W, Michels RPJ, et al. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia. 2008; 51(1): 183–190.
  3. Kawanishi S, Ohnishi S, Ma N, et al. Crosstalk between DNA Damage and Inflammation in the Multiple Steps of Carcinogenesis. Int J Mol Sci. 2017; 18(8).
  4. Dizdaroglu M, Jaruga P, Birincioglu M, et al. Free radical-induced damage to DNA: mechanisms and measurement. Free Radic Biol Med. 2002; 32(11): 1102–1115.
  5. de Zwart LL, Meerman JH, Commandeur JN, et al. Biomarkers of free radical damage applications in experimental animals and in humans. Free Radic Biol Med. 1999; 26(1-2): 202–226.
  6. Montuschi P, Corradi M, Ciabattoni G, et al. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med. 1999; 160(1): 216–220.
  7. Carpagnano GE, Kharitonov SA, Foschino-Barbaro MP, et al. Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation. Thorax. 2004; 59(12): 1016–1019.
  8. Kharitonov SA, Barnes PJ. Biomarkers of some pulmonary diseases in exhaled breath. Biomarkers. 2002; 7(1): 1–32.
  9. Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care. 1999; 22(2): 307–313.
  10. Vessby J, Basu S, Mohsen R, et al. Oxidative stress and antioxidant status in type 1 diabetes mellitus. J Intern Med. 2002; 251(1): 69–76.
  11. Novak BJ, Blake DR, Meinardi S, et al. Exhaled methyl nitrate as a noninvasive marker of hyperglycemia in type 1 diabetes. Proc Natl Acad Sci U S A. 2007; 104(40): 15613–15618.
  12. Habib MP, Dickerson FD, Mooradian AD. Effect of diabetes, insulin, and glucose load on lipid peroxidation in the rat. Metabolism. 1994; 43(11): 1442–1445.
  13. Vracko R, Thorning D, Huang TW. Basal lamina of alveolar epithelium and capillaries: quantitative changes with aging and in diabetes mellitus. Am Rev Respir Dis. 1979; 120(5): 973–983.
  14. Weynand B, Jonckheere A, Frans A, et al. Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration. 1999; 66(1): 14–19.
  15. Goldman MD. Lung dysfunction in diabetes. Diabetes Care. 2003; 26(6): 1915–1918.
  16. Ardigo D, Valtuena S, Zavaroni I, et al. Pulmonary Complications in Diabetes Mellitus: The Role of Glycemic Control. Current Drug Target -Inflammation & Allergy. 2004; 3(4): 455–458.
  17. Hsia CCW, Raskin P. The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am J Med. 2005; 118(3): 205–211.
  18. Kuitert LME. The lung in diabetes--yet another target organ? Chron Respir Dis. 2008; 5(2): 67–68.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl